Amedeo Smart

Free Medical Literature Service



Venous Thrombosis

  Free Subscription

Articles published in
Am J Hematol
    June 2021
  1. ABOU-ISMAIL MY, Moser KA, Smock KJ, Lim MY, et al
    Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism.
    Am J Hematol. 2021 Jun 7. doi: 10.1002/ajh.26265.
    >> Share

  2. TEFFERI A, Szuber N, Pardanani A, Hanson CA, et al
    Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
    Am J Hematol. 2021;96:E182-E184.
    >> Share

    May 2021
  3. KRECAK I, Gardijan B, Brkicic J, Grubisic-Cabo R, et al
    Cryptic brain abscess - do not forget hereditary hemorrhagic teleangiectasia!
    Am J Hematol. 2021;96:640-642.
    >> Share

    April 2021
  4. ARCHULETA J, van der Graaf M, Kaptein FHJ, Althaus L, et al
    Sudden death due to massive bone marrow sequestration crisis in a patient with sickle cell disease.
    Am J Hematol. 2021;96:E100-E102.
    >> Share

    March 2021
  5. WARKENTIN TE, Smythe MA, Ali MA, Aslam N, et al
    Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT?
    Am J Hematol. 2021;96:320-329.
    >> Share

    December 2020
  6. HANFF TC, Mohareb AM, Giri J, Cohen JB, et al
    Thrombosis in COVID-19.
    Am J Hematol. 2020;95:1578-1589.
    >> Share

    August 2020
  7. STEFELY JA, Christensen BB, Gogakos T, Cone Sullivan JK, et al
    Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25979.
    >> Share

    July 2020
  8. GUPTA VK, Strykowski R, Scarpato B, Lawrence R, et al
    The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease.
    Am J Hematol. 2020 Jul 3. doi: 10.1002/ajh.25923.
    >> Share

    October 2019
  9. CHALAYER E, Teste A, Guyotat D, Elalamy I, et al
    Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: external validation of the IMPEDE VTE score.
    Am J Hematol. 2019 Oct 15. doi: 10.1002/ajh.25658.
    >> Share

    August 2019
  10. SANFILIPPO KM, Luo S, Wang TF, Fiala M, et al
    Predicting Venous Thromboembolism in Multiple Myeloma: Development and Validation of the IMPEDE VTE Score.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25603.
    >> Share

  11. WYSOKINSKI WE, Houghton DE, Casanegra AI, Vlazny DT, et al
    Comparison of Apixaban to Rivaroxaban and Enoxaparin in Acute Cancer-Associated Venous Thromboembolism.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25604.
    >> Share

    May 2019
  12. BRUNSON A, Keegan T, Mahajan A, White R, et al
    High Incidence of Venous Thromboembolism Recurrence in Patients with Sickle Cell Disease.
    Am J Hematol. 2019 May 9. doi: 10.1002/ajh.25508.
    >> Share

    March 2019
  13. PEGOURIE B, Karlin L, Benboubker L, Orsini-Piocelle F, et al
    Apixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
    Am J Hematol. 2019 Mar 11. doi: 10.1002/ajh.25459.
    >> Share

    September 2018
  14. CHI G, Gibson CM, Liu Y, Hernandez AF, et al
    Inverse Relationship of Serum Albumin to the Risk of Venous Thromboembolism Among Acutely Ill Hospitalized Patients: Analysis from the APEX Trial.
    Am J Hematol. 2018 Sep 25. doi: 10.1002/ajh.25296.
    >> Share

    July 2018
  15. SOGAARD M, Nielsen PB
    Anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution.
    Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25164.
    >> Share

    June 2018
  16. STREIFF MB, Milentijevic D, McCrae K, Yannicelli D, et al
    An Answer to "Anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution" by Mette Sogaard and Peter Bronnum Nielsen.
    Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25165.
    >> Share

    May 2018
  17. CHEN YW, Wang MJ, Khorana AA
    Prevalence of Venous Thromboembolism Diagnosed in Emergency Department Visits by Cancer Patients and Associated Healthcare Resource Utilization in the United States.
    Am J Hematol. 2018 May 23. doi: 10.1002/ajh.25148.
    >> Share

    February 2018
  18. STREIFF MB, Milentijevic D, McCrae K, Yannicelli D, et al
    Effectiveness and Safety of Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Cancer.
    Am J Hematol. 2018 Feb 3. doi: 10.1002/ajh.25059.
    >> Share

    November 2017
  19. ALMAKADI M, Sheasgreen C, Barefah A, Lu L, et al
    The Risk of Venous Thromboembolism in Patients with Clinically Overt Gastrointestinal Bleeding.
    Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24967.
    >> Share

    August 2017
  20. COLTRO G, Mannelli F, Guglielmelli P, Pacilli A, et al
    A life-threatening ruxolitinib discontinuation syndrome.
    Am J Hematol. 2017;92:833-838.
    >> Share

    March 2017
  21. CHEN YW, Khorana A
    The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO Trial control arm.
    Am J Hematol. 2017 Mar 6. doi: 10.1002/ajh.24712.
    >> Share

    February 2017
  22. PATELL R, Rybicki L, McCrae KR, Khorana AA, et al
    Predicting Risk Of Venous Thromboembolism In Hospitalized Cancer Patients: Utility of A Risk Assessment Tool.
    Am J Hematol. 2017 Feb 27. doi: 10.1002/ajh.24700.
    >> Share

    January 2017
  23. OVANESOV MV, Menis MD, Scott DE, Forshee R, et al
    Association of Immune Globulin Intravenous (IGIV) and Thromboembolic Adverse Events (TEEs).
    Am J Hematol. 2017 Jan 9. doi: 10.1002/ajh.24644.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016